European phase 3/3b experience with long-acting cabotegravir and rilpivirine: efficacy, safety and virologic outcomes

被引：0
|
作者：
Molina, J. -M. [1 ]
Montes, M. L. [2 ]
Esser, S. [3 ]
De Castro, N. [1 ]
Patel, P. [4 ]
Dakhia, S. [5 ]
Polli, J. W. [4 ]
Garside, L. [6 ]
D'Amico, R. [4 ]
Talarico, C. [4 ]
Van Eygen, V. [7 ]
Vandermeulen, K. [7 ]
Spreen, W. R. [4 ]
Aboud, M. [5 ]
Bosse, M. [8 ]
机构：
[1] Univ Paris Diderot, St Louis Hosp, Infect Dis, Paris, France
[2] La Paz Univ Hosp, HIV Unit, Madrid, Spain
[3] Univ Hosp Duisburg Essen, Essen, Germany
[4] ViiV Healthcare, Res Triangle Pk, NC USA
[5] ViiV Healthcare, Brentford, England
[6] GlaxoSmithKline, London, England
[7] Janssen Res & Dev, Beerse, Belgium
[8] ViiV Healthcare, San Diego, CA USA
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/67
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [21] Top practices for implementing cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) in European clinics
    Olalla, Julian
    Gutner, Cassidy
    Pascual-Bernaldez, Miguel
    Hernandez, Beatriz
    Dakhia, Samia
    Slama, Laurence
    Crusells Canales, Maria Jose
    Lutz, Thomas
    van der Valk, Mark
    van Welzen, Berend
    Florence, Eric
    Barnes, Nicola
    Cooper, Owen
    Filipenko, Dina
    Czarnogorski, Maggie
    HIV MEDICINE, 2022, 23 : 27 - 28
  • [22] Safety and efficacy of cabotegravir plus rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results
    D'Amico, R.
    Orkin, C.
    Bernal Morell, E.
    Tan, D.
    Katner, H.
    Singh, Y.
    Stellbrink, H.
    Belonosova, E.
    DeMoor, R.
    Griffith, S.
    Thiagarajah, S.
    Van Solingen-Ristea, R.
    Crauwels, H.
    Ford, S.
    Patel, P.
    Cutrell, A.
    Smith, K.
    Vandermeulen, K.
    Margolis, D.
    St Clair, M.
    Spreen, W.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 10 - 12
  • [23] Preference-based measure of health from participants in Phase 3 studies of long-acting cabotegravir and rilpivirine for the treatment of HIV
    Wu, Sterling
    Jacob, Ian
    Van de Velde, Nicolas
    Chounta, Vasiliki
    HIV MEDICINE, 2021, 22 : 73 - 73
  • [24] Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine
    Hill, Lucas A.
    Abulhosn, Kari K.
    Yin, Jeffrey F.
    Bamford, Laura P.
    AIDS, 2023, 37 (04) : 605 - 609
  • [25] Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
    Swindells, Susan
    Lutz, Thomas
    Van Zyl, Lelanie
    Porteiro, Norma
    Stoll, Matthias
    Mitha, Essack
    Shon, Alyssa
    Benn, Paul
    Huang, Jenny O.
    Harrington, Conn M.
    Hove, Kai
    Ford, Susan L.
    Talarico, Christine L.
    Chounta, Vasiliki
    Crauwels, Herta
    Van Solingen-Ristea, Rodica
    Vanveggel, Simon
    Margolis, David A.
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Spreen, William R.
    AIDS, 2022, 36 (02) : 185 - 194
  • [26] Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine
    Maguire, Christina
    Rueve, Kaitlyn
    Farmer, Eric
    Huesgen, Emily
    Karaj, Antoneta
    Binkley, Amanda
    Mounzer, Karam
    Brizzi, Marisa
    Chary, Pallavi
    Sung, Peter
    Graziani, Amy
    Hiserodt, Emily
    Baron, Jillian
    Koenig, Helen
    Short, William R.
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [27] Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis
    Manalu, Samuel Bungaran Partahi Saud
    Navarro, Andrea Perez
    Fairhead, Cassandra
    Hill, Andrew
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2025, 80 (03) : 624 - 632
  • [28] Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic
    Liegeon, Geoffroy
    Kaperak, Christopher
    Friedman, Eleanor E.
    Djuricich, Paul
    Dawdani, Alicia
    Stafford, Kane
    Plotkin, Sophie
    Schmitt, Jessica
    Hazra, Aniruddha
    Christopoulos, Katerina A.
    Schneider, John A.
    Mcnulty, Moira C.
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (03):
  • [29] Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience
    Castelli, Alessandro
    Lanzafame, Massimiliano
    Morra, Matteo
    Bertoldi, Marco
    Delama, Andrea
    Fait, Daniela
    Vento, Sandro
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2024, 40 (05) : 283 - 285
  • [30] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
    Rizzardini, Giuliano
    Overton, Edgar T.
    Orkin, Chloe
    Swindells, Susan
    Arasteh, Keikawus
    Gorgolas Hernandez-Mora, Miguel
    Pokrovsky, Vadim
    Girard, Pierre-Marie
    Oka, Shinichi
    Andrade-Villanueva, Jaime F.
    Richmond, Gary J.
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Griffith, Sandy
    Harrington, Conn M.
    Hudson, Krischan J.
    St Clair, Marty
    Talarico, Christine L.
    Patel, Parul
    Cutrell, Amy
    Van Eygen, Veerle
    D'Amico, Ronald
    Mrus, Joseph M.
    Wu, Sterling
    Ford, Susan L.
    Chow, Ken
    Roberts, Jeremy
    Wills, Angela
    Walters, Nicola
    Vanveggel, Simon
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Smith, Kimberly Y.
    Spreen, William R.
    Margolis, David A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) : 498 - 506
12345